Emerging therapies for Intracerebral Hemorrhage



Similar documents
Anticoagulation and Reversal

Stop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery

Critical Bleeding Reversal Protocol

Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services

LAMC Reversal Agent Guideline for Anticoagulants Time to resolution of hemostasis (hrs) Therapeutic Options

High Risk Emergency Medicine

STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE

Acute Myocardial Infarction (the formulary thrombolytic for AMI at AAMC is TNK, please see the TNK monograph in this manual for information)

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012

Blood products and pharmaceutical emergencies

3/3/2015. Patrick Cobb, MD, FACP March 2015

9/5/14. Objectives. Atrial Fibrillation (AF)

48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact.

The author has no disclosures

10/16/2013. Reversal of Anticoagulants: Something New Under the Sun? Disclosures. Pharmacist Objectives

NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl

Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center

EMS Management of Stroke. Deaver Shattuck, M.D. Brian Wiseman, M.D. Keith Woodward, M.D.

New Anticoagulants: When and Why Should I Use Them? Disclosures

Reversal of Anticoagulants at UCDMC

Disclosures. Objective (NRHS) Self Assessment #2

Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness SOGH April

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

The management of cerebral hemorrhagic complications during anticoagulant therapy

Disclosure. Outline. Objectives. I have no actual or potential conflict of interest in relation to this presentation.

New Oral Anticoagulants

New in Atrial Fibrillation

5/21/2012. Perioperative Use Issues. On admission: During hospitalization:

Level III Stroke Center Data Collection Requirements

How does warfarin work? We know itʼs a vitamin k antagonist, but what does that mean? What's really getting antagonized?

Anticoagulant Reversal

Speaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

New Anticoagulants and GI bleeding

Novel oral Anticoagulants, stroke and intracerebral hemorrhage

Novel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015

The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences

DVT/PE Management with Rivaroxaban (Xarelto)

What s New in Stroke?

UPDATED INCLUSION AND EXCLUSION CRITERIA FOR IV TPA ADMINISTRATION ACUTE STROKE TREATMENT: AN UPDATE GOALS OF TALK

How To Treat Aneuricaagulation

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

Oral anticoagulants new and old: bleeding risk and management strategies. Logan Tinsen Pharm.D. Benefis Hospitals

Anticoagulants in Atrial Fibrillation

Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation

Guidelines and Protocols

Pulmonary Embolism Treatment Update

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab

STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach

TPA, STROKE, & TELEMEDICINE. Improving utilization and improving outcomes in a constantly evolving field

Anticoagulation Essentials! Parenteral and Oral!

Using the Pupillometer in Clinical Practice

The Brave New (Anticoagulant) World

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

Impact of new (direct) oral anticoagulants in patient blood management

Accreditation and Certification Guidelines

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

JHS Stroke Program JHS Annual Mandatory Education

Title of Guideline. Thrombosis Pharmacist)

Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care

Anticoagulation Therapy Update

Anticoagulation in Atrial Fibrillation

Non- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose. Warfarin vs the NOACs

Managing Anticoagulation for Atrial Fibrillation 2015

Making Sense of the Newer Anticoagulants

Stroke Care First week

MANAGING BLEEDING IN THE

Anticoagulants. Anticoagulants Definition. When are blood clots GOOD? Where and why do blood clots occur? 6/12/2014

NICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation

NOACS AND AF PEARLS AND PITFALLS DR LAURA YOUNG HAEMATOLOGIST

The Anticoagulated Patient A Hematologist s Perspective

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

What to do in case of hemorragia. L Camoin Jau Service d Hématologie APHM Marseille

Goals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD

SCRN Medication Review. Susan M. Gaunt MS APRN ACNS-BC CCRN CNRN Gwinnett Medical Center

To assist clinicians in the management of minor, major, and/or life-threatening bleeding in patients receiving new oral anticoagulants (NOACs).

New Anticoagulants: What to Use What to Avoid

Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012

Let s talk about: Stroke

Anticoagulants for stroke prevention in atrial fibrillation Patient frequently asked questions

New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis

1/12/2016. What s in a name? What s in a name? NO.Anti-Coagulation. DOACs in clinical practice. Practical aspects of using

STROKE PREVENTION IN ATRIAL FIBRILLATION

Directed to Dr. Carrier from NBRHC audience Q: In patients with GI Bleed history, would you suggest Apixaban for newly diagnosed patients

Anticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h

Bios 6648: Design & conduct of clinical research

AR SAVES. INTRODUCTION AND UPDATES FOR ER PHYSICIANS. Nicolas Bianchi, MD. August 23 rd, 2012.

A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs

Therapeutic Management Options for. Acute Ischemic Stroke Anna Rosenbaum, MD

Transcription:

Emerging therapies for Intracerebral Hemorrhage Chitra Venkat, MBBS, MD, MSc. Associate Professor of Neurology and Neurological Sciences Stroke and Neurocritical Care. Stanford University

Learning objectives Update on emerging trends in ICH for Blood pressure management Anticoagulation reversal Surgical advances

Patient KK 80 year old male Very active, independent. Well controlled hypertension, hyperlipidemia, remote smoking, social EtOH. Collapsed in the bathroom, not moving left side, awake, dysarthric, right gaze preference, left hemiplegia, neglect, following commands.

110 cc right basal ganglia ICH with IVH.

Audience question 1 Which of Mr. KK s risk factors put him at risk for the ICH? High cholesterol High blood pressure High blood sugar Smoking

Risk factors for primary ICH 1. Older age 2. Hypertension 3. ETOH abuse 4. Prior ICH 5. Anticoagulation 6. Carriers of apolipoprotein 2 or 4 allele

Types of spontaneous (i.e. nontraumatic) Intracerebral Hemorrhage Primary (80-90%) Hypertension Cerebral amyloid angiopathy Secondary

Tis a rare thing.but 85% Ischemic 15% Hemorrhagic Brain / Subarachnoid 25% Large Vessel Atherosclerosis 20% Embolism from Heart 30% Undetermined 20% Small Vessel Atherosclerosis 5% Unusual Causes

ICH remains a devastating stroke. Only ~ 20% are fully independent at 6 months Mortality: 6 months, 30-50% American Heart Association. Heart Disease and Stroke Statistics 2008 Update. 1.

ICH PATHOPHYSIOLOGY & OUTCOME ICH MORTALITY AND MORBIDITY EXCITOTOXICITY MEIDATED CELL INJURY

ICH score and mortality at 1 month Patient KK s ICH score = 3

Functional outcome at 90 days

Dilemma With a predicted 70% mortality at 1 month and 0% chance of functional recovery, in this 80 year old male, what should I advise him and his family? Oh, BTW, his daughter is an ICU nurse at my hospital.

The self fulfilling prophecy in ICH Current methods of prognostication in individual patients early after ICH are likely biased by failure to account for the influence of withdrawal of support and early DNR orders. Aggressive full care early after ICH onset and postponement of new DNR orders until at least the second full day of hospitalization is probably recommended.

How I view ICH related outcome Excellent medical care has a potent, direct impact on ICH morbidity and mortality, even before a specific therapy is found. In many cases, it is the aggressiveness of clinical care that determines the direct mortality from the disease.

ICH outcomes are improved in a neuroicu Initial monitoring and management of ICH patients should take place in an intensive care unit with physician and nursing neuroscience intensive care expertise Class 1 recommendation. AHA ICH guidelines, Stroke 2010

Can we and if so, how to change Only ~ 20% are fully independent at 6 months ICH outcome? Mortality: 6 months, 30-50% American Heart Association. Heart Disease and Stroke Statistics 2008 Update. 1.

THERAPEUTIC TARGETS IN ICH HEMATOMA EXPANSION BLOOD PRESSURE CONTROL HEMOSTATIC THERAPIES CLOT REMOVAL MASS EFFECT FROM HEMATOMA & EDEMA ANTI-INFLAMMATORY THERAPIES

Emergency ICH management Principles Stop ongoing bleeding Prevent hematoma expansion Accelerate removal blood from the brain

Emergency ICH management Principles Stop ongoing bleeding Prevent hematoma expansion

Strategies to limit ICH expansion. Reducing the driving force (i.e. Blood pressure). Treating the compromised coagulation.

BP lowering after ICH: Competing interests Hematoma expansion Vs penumbra

Audience question 2 The optimal systolic blood pressure goal for blood pressure lowering in the first day after ICH is 180 mm Hg 160 mm Hg 140 mm Hg

My approach to BP lowering in ICH (in 2013) For small ICH (< 25 cc)- BP lowering to SBP < 140 mm Hg seems reasonably safe. (Interact 2 study) For larger ICH- I lower to SBP < 160 mm Hg or MAP of < 110 mm Hg (AHA guideline, Class 2b) In young normotensives, coagulopathy, vascular lesion- < 140 mm Hg is reasonable. ATACH-2: NIH funded, Phase 3, RCT, iv nicardipine, < 140 Vs 140-180 mm Hg.

Emergency ICH management Principles Stop ongoing bleeding Prevent hematoma expansion

76yo M, ICH, INR=5.5 Non Con CT @ 60 mins post sx onset R pupil becomes fixed in ED, follow up CT 140 mins later shows interval expansion

Audience response question # 3 Which of the following is the best strategy for emergency warfarin reversal? A.Subcutaneous Vit K + FFP B.Intravenous Vit K + FFP C.Intravenous Vit K + Profilnine (3F- PCC) D.Intravenous Vit K + Kcentra (4F-PCC)

Novoseven* Prothrombin Complex VII a IXa VII a IIa Xa IXa Warfarin Plasma VII a Xa Va IIa IXa Ia Platelet transfusion Rivaroxaban Apixiban Xa Xa XIII Va IIa IIa XIIIa V IIa Dabigatran PAR I IIa Ia Acid ε aminocaproi - Plasmin Antiplatelet agents Vitamin K Adapted from: Dr. Jean-Marc Olivot

Stanford emergency warfarin reversal protocol INR 1.2-1.5 INR 1.6 Vit K 5 mg IV + Liquid Plasma 1-2 units Vit K 10 mg IV + Liquid Plasma 2-3 units Recheck INR in 15-30 INR 4 Profilnine 25 units/kg INR > 4 Profilnine 35-50 units/kg INR 1.2 INR > 1.2 INR q6 till 2 readings 1.2 FFP 1 unit INR > 1.2 at 24 hrs, repeat Vit K 5 mg Recheck INR after Plasma infusion INR 1.2 INR q6 till 2 readings 1.2 INR > 1.2 FFP 2 units+/- PCC repeat if > 6 hrs.

Does the protocol work? 80 year old woman with INR 18.9. The warfarin reversal protocol was implemented INR 1.1 reached within 2 hours. She has since returned home with minimal deficits.

FDA approves Kcentra- 4 factor PCC, 4/2013 4F PCC- 2, 7, 9, 10, protein C & S Kcentra + Vitamin K Vs FFP + Vitamin K (n=212) INR < 1.3 at 30 minutes in 63% Vs 9% 87% less volume (~ 100 cc Vs 900 cc) 7 fold faster infusion time (24 min Vs 3 hrs) Sarode, Circulation, 2013.

Stanford emergency warfarin reversal protocol INR < 2 INR 2 Vit K 5 to 10 mg IV + Liquid Plasma 1-2 units Vit K 10 mg IV Recheck INR in 15-30 min INR 2- <4 KCentra 25 units/kg max. 2500 units INR 4-6 Kcentra 35 units/kg max. 3500 units INR >6 Kcentra 50 units/kg max. 5000 units INR 1.4 INR > 1.4 INR q8h FFP 1-2 U INR > 1.4 at 24 hrs, repeat Vit K 5 mg Recheck INR within 30 min. **repeat dosing with Kcentra not recommended # For INR 1.7-2, Kcentra can be considered.

Reversal of newer oral anticoagulants No specific antidote yet Pilot trial of dabigatran reversal agent is being planned For now Hemodialysis for dabigatran if within 6 hours 4F- PCC as off label use for apixiban and rivaroxaban.

Emergency ICH management Principles Accelerate removal blood from the brain

THERAPEUTIC TARGETS IN ICH HEMATOMA EXPANSION BLOOD PRESSURE CONTROL HEMOSTATIC THERAPIES CLOT REMOVAL MASS EFFECT FROM HEMATOMA & EDEMA ANTI-INFLAMMATORY THERAPIES

Audience question Open craniotomy is currently recommended for which of the following hematomas? A B C D

Audience question Open craniotomy is currently recommended for which of the following hematomas? A B C D

When do I call the neurosurgeon??? Moderate or large lobar/superficial hemorrhage when deteriorating Cerebellar hemorrhage > 3cm with deterioration or brainstem compression and/or hydrocephalus Nonsurgical candidates: small ICH / minimal neurologic deficits and a low LOC

How about minimally invasive surgery?

MISTIE- minimally invasive surgery + tpa for ICH evacuation

What happened to Mr. KK? Pre-surgery Immediate post op. 1 dose tpa. 48 hours.

180 & 365-Day modified Rankin Scale 11% 14% 21% LTCF 14% 44

38 days (35%) $ 44K (35%) 45

TPA Accelerates Intraventricular Clot Lysis.

Intraventricular tpa- 2 doses

How did Mr. KK do? Was never intubated Went to acute rehab after 3 weeks Is now home; in great spirits Able to stand with assistance (2 months after ICH), left neglect improving Can wheel himself around, cognitively intact, speaking well.

Take home points 1. ICH patients need aggressive treatment in a neuroscience ICU. 2. BP can probably be safely reduced to 140/90 mm Hg over the first 24 hours. 3. Anticoagulation should be promptly reversed. 4. Surgery is indicated only in select patients. 5. Prognostication is best done by an expert keeping in mind that 1/3 rd of patients improve up to one year and beyond.

The Stanford Stroke Center